Spolier alert: Actually no-one because Cytodyn does not have any marketable products but if they did….
What a way to start the week, the long awaited “Distribution Agreement” news has finally been released by everyone’s favorite reverse merger pink sheet Coronacrapper, Cytodyn (CYDY).
Readers might recall that on June 2, 2020 The Nadir had this to say:
OK, a non-binding term sheet “with a pretty well known company.” Sounds like absolutely nothing. And on June 11th, The Nadir and Mike Mulholland provided this update:
And now, today July 6th, 2020 we get the big reveal. Just who is lucky enough to “distribute”* Cytodyn’s wonder drug, leronlimab?
American Regent! Surely a “pretty well known company”. Never heard of them? Prior to 2019 they were known as Luitpold Pharmaceuticals. Never heard of them? Well you might know them from their previous incarnation as Luitpold-Werk. No?
Although the details are few, it appears to be a deal with zero risk for American Regent. Until and unless leronlimab gets an EUA or an approval for Covid-19, there is nothing to distribute. There appear to be no commitment, and American Regent doesn’t get a standard distribution mark-up, they actually get a profit split. The bidding over leronlimab must have been INTENSE.
A quick perusal of the American Regent web site shows they are a distributor of mundane IV vitamin and minerals (31 different SKUs mostly different dosages of a few products) and a few low value generic drugs. (36 SKUs, most just different dosages of a few products).
One thing that DOES make American Regent a perfect partner for Cytodyn, however, is this curious section of their website, devoted to their distribution of products UNapproved by the FDA! Surely a perfect match.
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.